Zanaflex (Tizanidine) Dosage
For adults with normal hepatic and renal function, start Zanaflex at 2-4 mg orally and titrate gradually by 2-4 mg increments every 1-4 days, with a maximum dose of 36 mg/day divided into three doses; in severe renal or hepatic impairment, avoid use or use extreme caution with significantly reduced doses and close monitoring. 1
Adult Dosing
Standard Initiation and Titration:
- Starting dose: 2-4 mg orally
- Titration: Increase by 2-4 mg per dose every 1-4 days as needed
- Usual effective dose: 8 mg per dose, given three times daily
- Maximum daily dose: 36 mg/day (divided into 3-4 doses)
- Single dose maximum: Limited long-term experience exists with single daytime doses >16 mg 1
The wide interpatient variability in effective plasma concentrations necessitates individualized dose titration over 2-4 weeks, with dosages ranging from 2-36 mg/day used in clinical trials 2. Maximum antispastic effects occur within 2 hours of administration 2.
Pediatric Dosing
Tizanidine is NOT FDA-approved for pediatric use 1. However, off-label use has been studied:
- Ages 18 months to 7 years: Start 1 mg/day 3
- Ages 7-12 years: Start 2 mg/day 3
- Ages >12 years: Use adult dosing 3
- Weight-based dosing: 0.1-0.2 mg/kg/day divided into 2-3 doses has been used for spastic quadriplegia 4
Critical pediatric safety concern: A case report documented severe liver, renal, and cardiovascular failure in a 2-year-old after unintentional overdose (1.6 mg/kg/day), worsened by dehydration 5. This underscores the narrow therapeutic index and need for extreme caution in children.
Severe Renal Impairment (Creatinine Clearance <25 mL/min)
Tizanidine clearance is reduced by >50% in elderly patients with renal insufficiency 1.
- Use with caution and close monitoring 1
- Reduce individual doses (not frequency) during titration 1
- Monitor closely for dry mouth, somnolence, asthenia, and dizziness as indicators of potential overdose 1
- The longer duration of clinical effect necessitates careful dose adjustment 1
Severe Hepatic Impairment
Tizanidine should ordinarily be avoided or used with extreme caution in hepatic impairment 1. The rationale:
- Tizanidine is extensively metabolized in the liver (95% of dose) via CYP1A2 1
- Approximately 5% of patients develop liver function test elevations >3 times upper limit of normal 1
- Rare deaths from liver failure have been reported postmarketing 1
- Monitoring requirement: Check aminotransferases at baseline, 1,3, and 6 months, then periodically 1
If use is deemed absolutely necessary despite hepatic impairment, start with the lowest possible dose and monitor intensively for hypotension, sedation, and worsening liver function.
Critical Drug Interactions Requiring Dose Modification
CONTRAINDICATED combinations (do not use together):
- Fluvoxamine: Increases tizanidine Cmax 12-fold and AUC 33-fold 1
- Ciprofloxacin: Increases tizanidine Cmax 7-fold and AUC 10-fold 1
Both cause severe hypotension, drowsiness, and psychomotor impairment 1.
Use with extreme caution (avoid if possible):
- Other CYP1A2 inhibitors: zileuton, other fluoroquinolones, amiodarone, mexiletine, propafenone, verapamil, cimetidine, famotidine, acyclovir, ticlopidine 1
- Oral contraceptives: Reduce tizanidine clearance by 50% 1. If concomitant use is necessary, reduce starting dose and slow titration rate 1
Formulation-Specific Considerations
Tablets vs. Capsules with Food:
- Tablets with food: Cmax increases 30%, time to peak increases by 25 minutes 1
- Capsules with food: Cmax decreases 20%, time to peak increases by 2 hours to 3 hours 1
- Capsules on applesauce: 15-20% increase in Cmax and AUC versus intact capsule fasting 1
These differences can alter efficacy and adverse effect profiles; maintain consistency in administration relative to meals 1.
Key Safety Warnings
Hypotension: Two-thirds of patients on 8 mg experience 20% reduction in BP, peaking 2-3 hours post-dose, with risk of syncope 1. The effect is dose-related starting at ≥2 mg 1.
Sedation: 48% report sedation (10% severe), with 92% drowsy at 16 mg dose 1. This is dose-related and peaks in the first week of titration 1.
Discontinuation: Taper slowly to minimize rebound hypertension, tachycardia, and hypertonia 1.